$0.4630
-0.14-22.7%
Last update: Nov 10, 8:59 AM
Lantern Pharma Inc
LTRNNASDAQ
Lantern Pharma fell 83.1% from $3.55 to $0.60, behind the S&P 500's +10.0%. Its worst day was Mar 27 (−46.4%), and its low came Nov 5 at $0.53.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.39 beat the $-0.46 estimate on $0.00 revenue.
−0.6% · S&P 500 −1.7%
EPS of $-0.36 beat the $-0.45 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
+10.9%, on 15M shares, the year's heaviest volume · S&P 500 +2.9%
EPS of $-0.30 beat the $-0.36 estimate on $0.00 revenue.
−4.5% · S&P 500 −0.1%
Lantern Pharma closed at its highest level of the year, 17.5% above where the year started.
+2.5% · S&P 500 +0.8%
EPS of $-0.57 missed the $-0.38 estimate on $0.00 revenue.
+0.8% · S&P 500 −0.2%
Lantern Pharma shares rose 20.9%, while the S&P 500 rose 0.3%.
+20.9% · S&P 500 +0.3%
Where it ended: a close of $0.60 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.38).
Nothing in the past 12 months.
All LTRN analyst actionsNothing in the past 12 months.
All LTRN dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for LTRN and SPY from Benzinga historical bars. Not investment advice.
